Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...